Remove 2013 Remove Pharma Remove Prescription Remove Safety
article thumbnail

AbbVie CEO looks like a fool before Congress

World of DTC Marketing

While AbbVie is a poster for everything wrong with pharma, what they have done doesn’t apply to ALL pharma companies. According to CNBC “AbbVie workers say they worry that the company is putting profits ahead of safety and the health of its U.S. billion on R&D from 2013 to 2018. Why the increase?

Pharma 181
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf. 1435 (“Affordable Prescriptions for Patients Act of 2021”), [link] gov/bill/117th-congress/senate-bill/1435/text; H.R. Actavis, 570 U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

More FDC products flowing into pharma pipelines. From 1990 through 2013, the FDA approved 131 FDC products, on average 5.7 Improved convenience and safety. Replacing two or three pills with a single FDC drug product also translates into less time spent filling (and refilling) prescriptions. The numbers tell the story.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). One Phase II trial was completed back in 2013, as per ClinicalTrials.gov. Emotional Brain worked on these two tablets for much of the past decade.